Patent ID: 8784812

Claim:
A method for treatment of rheumatoid arthritis in a human patient comprising administering to the patient a composition comprising a fusion molecule selected from the group consisting of: (a) a fusion molecule comprising (i) TACI extracellular domain wherein said TACI extracellular domain is at least 95% identical to SEQ ID NO:1 and binds BlyS; and (ii) a human immunoglobulin-constant domain; (b) a fusion molecule comprising amino acids 30-110 of SEQ ID NO: 1 and a human immunoglobulin-constant domain; (c) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO: 1 and a human immunoglobulin-constant domain; (d) a fusion molecule consisting of SEQ ID NO: 2; and (e) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:1 and the human immunoglobulin-constant domain of SEQ ID NO: 2; wherein said composition is administered in an amount from 1.0 mg per 1 kg of patient's body weight to 9.0 mg per 1 kg of patient's body weight and wherein said composition is administered in said amount 7 times during a twelve-week interval, 3 times during a four-week interval or every other week for 2 to 30 weeks.